Foghorn Therapeutics Inc.: Form 10-Q for the period ended Sep 30, 2020
Filed with the SEC on Dec 4, 2020 and accepted by EDGAR at Dec 4, 2020, 16:51 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2020-07-01 to 2020-09-30 | $179.0k | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2020-01-01 to 2020-09-30 | $179.0k | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months2020-07-01 to 2020-09-30 | $16.1m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2020-01-01 to 2020-09-30 | $41.2m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2020-07-01 to 2020-09-30 | −$18.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2020-01-01 to 2020-09-30 | −$47.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2020-07-01 to 2020-09-30 | $202.0k | us-gaap:InterestExpense |
| Interest expense | 9 months2020-01-01 to 2020-09-30 | $658.0k | us-gaap:InterestExpense |
| Net income | 3 months2020-07-01 to 2020-09-30 | −$18.4m | us-gaap:NetIncomeLoss |
| Net income | 9 months2020-01-01 to 2020-09-30 | −$48.0m | us-gaap:NetIncomeLoss |
| Operating cash flow | 9 months2020-01-01 to 2020-09-30 | −$20.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2020-01-01 to 2020-09-30 | $8.7m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2020-09-30 | $74.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-09-30 | $77.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2020-09-30 | $142.4m | us-gaap:Assets |
| Current liabilities | At period end2020-09-30 | $21.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-09-30 | $99.3m | us-gaap:Liabilities |
| Long-term debt | At period end2020-09-30 | $8.8m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2020-09-30 | $6.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2020-09-30 | −$133.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001193125-20-310715. Last ingested by Listed: Nov 9, 2026, 17:27 ET. Listed shows no prices and gives no investment advice.